moatshark My

All holdings

Billiontoone

BLLN

Source: the SEC Form 13F filings of the managers we follow, latest for Q3 2026. How we use them

Managers holding
1
In their latest 13F (Q3 2026)
See who
Value held
$2.0m
Combined value at quarter end
Last quarter
1 bought
0 sold or trimmed
Price at Q2 ’26 end
$119.98

Prices here are quarter-end prices implied by the 13F filings. Today’s price on Yahoo Finance

Managers holding it, by quarter

0Q4 ’23
0Q1 ’24
0Q2 ’24
0Q3 ’24
0Q4 ’24
0Q1 ’25
0Q2 ’25
0Q3 ’25
0Q4 ’25
0Q1 ’26
1Q2 ’26
0Q3 ’26
Q4 ’23: 0; Q1 ’24: 0; Q2 ’24: 0; Q3 ’24: 0; Q4 ’24: 0; Q1 ’25: 0; Q2 ’25: 0; Q3 ’25: 0; Q4 ’25: 0; Q1 ’26: 0; Q2 ’26: 1; Q3 ’26: 0

Counts the managers on this site whose 13F for that quarter includes Billiontoone.

Who holds it

Each manager’s latest 13F, sorted by how much of their portfolio it is. Changes are against their previous quarter.

Managers holding Billiontoone
Polen Capital Management0.0%$2.0m$2.0mNew1 qtr

Download the holders: CSV · JSON · Markdown

Directors buying and selling

Open-market trades by directors, officers and 10% holders over the last 12 months. How this works
From their Form 4 filings with the SEC. Grants, option exercises and shares sold to pay tax are left out.
Insider purchases and sales of Billiontoone
Bought or soldFiling
15 Oct 2026Atay OguzhanChairman and CEO▼ Sold1,861$99.84$186kForm 4
15 Oct 2026Atay OguzhanChairman and CEO▼ Sold1,276$100.60$128kForm 4
15 Oct 2026Atay OguzhanChairman and CEO▼ Sold980$101.79$100kForm 4
15 Oct 2026Atay OguzhanChairman and CEO▼ Sold900$98.43$89kForm 4
15 Oct 2026Atay OguzhanChairman and CEO▼ Sold133$102.78$14kForm 4
14 Oct 2026Atay OguzhanChairman and CEO▼ Sold3,083$98.32$303kForm 4
14 Oct 2026Atay OguzhanChairman and CEO▼ Sold2,667$98.00$261kForm 4
14 Oct 2026Atay OguzhanChairman and CEO▼ Sold100$99.00$10kForm 4
12 Oct 2026Atay OguzhanChairman and CEO▼ Sold6,763$93.65$633kForm 4
12 Oct 2026Atay OguzhanChairman and CEO▼ Sold3,869$94.61$366kForm 4
12 Oct 2026Atay OguzhanChairman and CEO▼ Sold2,667$97.61$260kForm 4
12 Oct 2026Atay OguzhanChairman and CEO▼ Sold2,553$93.05$238kForm 4
12 Oct 2026Atay OguzhanChairman and CEO▼ Sold1,961$91.57$180kForm 4
12 Oct 2026Atay OguzhanChairman and CEO▼ Sold1,521$96.39$147kForm 4
5 Oct 2026Tsao DavidChief Technology Officer▼ Sold4,916$108.53$534kForm 4
5 Oct 2026Tsao DavidChief Technology Officer▼ Sold4,284$108.39$464kForm 4
5 Oct 2026Tsao DavidChief Technology Officer▼ Sold2,921$109.00$318kForm 4
5 Oct 2026Tsao DavidChief Technology Officer▼ Sold2,200$107.47$236kForm 4
5 Oct 2026Tsao DavidChief Technology Officer▼ Sold1,909$107.19$205kForm 4
5 Oct 2026Tsao DavidChief Technology Officer▼ Sold1,829$109.14$200kForm 4

About the company

Sector
Health care · Services-Medical Laboratories
Incorporated in
Delaware
Financial year ends
31 December
SEC filings
Annual reports and other filings on EDGAR

Revenue and profit

$71.7m2023
$153m2024
$305m2025
2023: $71.7m; 2024: $153m; 2025: $305m
Billiontoone revenue and net income by year
YearRevenueNet income
2025$305m$7.5m
2024$153m−$41.6m
2023$71.7m−$82.7m

From the company’s XBRL financial statements filed with the SEC, for each financial year. Gaps mean the company didn’t report that figure in a standard form.